Friday, January 6, 2012

Oncothyreon Names Chief Medical Officer

Seattle-based Oncothyreon, which is developing treatments for cancer, said yesterday that it has promoted Diana Hausman, M.D., to the position of Chief Medical Officer. Hausman has been Vice President, Clinical Development at the firm since August of 2009. Hausman has previously also served at Zymogenetics and Berlux. Oncothyreon is focused on developing small molecules and synthetic vaccines for the oncology market.